fda amgen - Search News

FDA, Amgen and Obesity

Bloomberg on MSN · 2d

Amgen Discloses FDA Paused Study of Early-Stage Obesity Drug

Amgen Inc. sees the potential for 2025 revenues to top Wall Street estimates thanks to growth in cholesterol and cancer drugs.

Study of Amgen’s early obesity candidate paused by FDA

The company said the agency's hold was "not related to the drug,” dubbed AMG 513, and that discussions were underway to reopen the study.

FierceBiotech · 2d

Amgen's early-stage obesity asset slapped with FDA hold

Amgen’s mysterious obesity asset will remain a mystery for a bit longer—the FDA has put the candidate’s phase 1 trial

2d

Amgen profits rise, next MariTide studies start by mid-year

Amgen posted a higher quarterly profit on Tuesday as product sales rose 11% and said late-stage studies of key obesity drug ...

With recent launches and more to come, Amgen's biosimilar business is trending up

After recent launches of biosimilar versions of Eylea and Stelara, Amgen projects its biosimilar sales will reach $4 billion ...

Pipeline Problems Mar Amgen’s Q4 Beat

Amgen outperformed expectations in the fourth quarter of 2024, but revealed an FDA hold on early-stage obesity asset AMG 513 ...

9h

Amgen: Multiple Strengths, But The Valuation Is A Concern

Amgen's dividend yield remains attractive, with a moderate payout ratio and strong free cash flow. Click here to see why AMGN ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results